galyfilcon A
Devicegalyfilcon A
NCT Number: NCT00762385
The objective of this study is to evaluate the clinical performance of two silicone-hydrogel contact lenses.
Looking for future studies?
Notify Me18 year–39 year
All sexes
Interventional
Not applicable
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
galyfilcon A
comfilcon A
Time frame: 1-week, 2- weeks
>0 = comfortable, <0 = uncomfortable; a weighted combined score calculated from individual comfort-related questions was used to derive comfort outcomes.
Time frame: 1-week, 2-weeks
A weighted combined score calculated from individual comfort-related questions was used to derive comfort outcomes. >0 = comfortable, <0 = uncomfortable
Time frame: 2 weeks
Measured for 5 zones of the cornea (superior, nasal, central, inferior, temporal)on a 0 to 3 grade scale (NEI 0-3 scale). Grade 0 = Normal/ grade 1 = mild, superficial stippling/ grade 2 = moderate, punctate staining including superficial abrasion of the cornea/ grade 3 = severe, abrasion or corneal erosion, deep corneal abrasion or recurrent erosion.
Johnson & Johnson Vision Care, Inc.
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04075591
Eye Diseases, Refractive Error
Los Angeles, California, United States
View Trial DetailsNCT07168564
Ametropia, Eye Diseases
Bloomington, Indiana, United States
View Trial DetailsNCT05656027
Eye Diseases, Myopia
Chandler, Arizona, United States
View Trial DetailsNCT05753189
Eye Diseases, Myopia
Dothan, Alabama, United States
View Trial Details